Previous 10 | Next 10 |
2023-11-30 07:30:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips After a rocky couple of years, there finally seems to be some light at the end of the tunnel for growth stocks . Interest rates have stabilized, and the economy is again showing signs of st...
2023-11-24 04:34:34 ET Summary Viatris shares had a negative 25% total return in the past 2 years, underperforming the S&P 500. The decline is likely due to the company's debt burden and stagnant revenues. Despite this, now may be a good time to consider buying VTRS as its...
Community Activity Part of Company's Impact Week Anniversary Celebration PITTSBURGH, PA / ACCESSWIRE / November 21, 2023 / Viatris (NASDAQ:VTRS), a global healthcare company, today announced that it has packed 1,000 backpacks in partnership with Comfort Cases, a nonprofit organization th...
2023-11-21 13:48:38 ET Summary VTRS reported Q3-2023 earnings in line with estimates, with total sales down 3.3%. Adjusted EBITDA fell again, and new product launches are not delivering the same margins as the old business. We look at the progress made since its listing and te...
2023-11-19 02:00:00 ET Summary Legend Biotech partners with Novartis in a $1.2 billion deal to develop and commercialize DLL3 CAR-T candidates. WuXi XDC, an ADC/bioconjugate CRDMO, raises $520 million in a successful IPO in Hong Kong. Shanghai SciClone Pharma acquires China ri...
2023-11-15 13:59:19 ET More on Vertex Pharma Vertex Pharmaceuticals Incorporated (VRTX) Jefferies Global Healthcare Conference Call Transcript Vertex Pharmaceuticals Incorporated (VRTX) Presents at UBS Biopharma Conference (Transcript) No Dividend, No Problem: Vertex...
Viatris to Participate in the Jefferies London Healthcare Conference PR Newswire PITTSBURGH , Nov. 14, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the company will participate in the Jefferies London Healthca...
Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) PR Newswire Top-line results from Phase III study in China demonstrate the effica...
2023-11-09 23:34:44 ET Summary Davis Selected Advisers' 13F portfolio decreased by 3% to $15.95B this quarter. The top three holdings in the portfolio are Meta Platforms, Berkshire Hathaway, and Wells Fargo. A new stake was established in MGM Resorts International, while stake...
2023-11-07 21:37:12 ET Viatris Inc. (VTRS) Q3 2023 Earnings Conference Call November 7, 2023, 05:00 PM ET Company Participants William Szablewski - Head of Global Capital Markets Scott Smith - CEO Rajiv Malik - President Sanjeev Narula - CFO David Bayles ...
News, Short Squeeze, Breakout and More Instantly...
NORTHAMPTON, MA / ACCESSWIRE / July 23, 2024 / No country can make every medicine people need, and no medicine is made in every country. If a country or region relies on supply only from within their region and they experience a crisis, there is a risk people won't get the medicines they need, w...
NORTHAMPTON, MA / ACCESSWIRE / July 18, 2024 / Viatris is a global healthcare company focused on bringing high-quality medicines to patients through a hybrid approach that bridges the traditional divide between generics and brands, combining the best of both, to more holistically address healthc...
2024-07-15 10:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...